Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review
Intrahepatic cholangiocarcinoma (ICC) is one of the most common invasive malignant tumors, with a 5-year survival rate of less than 5%. Currently, radical surgical resection is the preferred treatment for ICC. However, most patients are only diagnosed at an advanced stage and are therefore not eligi...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2023-08-01
|
| Серии: | Frontiers in Immunology |
| Предметы: | |
| Online-ссылка: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1230261/full |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|